Details

Autor(en) / Beteiligte

• Heeger, Christian-Hendrik
• Abdin, Amr
• Mathew, Shibu
• Reissmann, Bruno
• Yalin, Kivanc
• Liosis, Spyridon
• Fink, Thomas
• Proietti, Riccardo
• Eitel, Charlotte
• Vogler, Julia
• Lemeš, Christine
• Maurer, Tilman
• Rillig, Andreas
• Meyer-Saraei, Roza
• Graf, Tobias
• Wohlmuth, Peter
• Goldmann, Britta
• Ouyang, Feifan
• Kuck, Karl-Heinz
• Metzner, Andreas
• Tilz, Roland Richard

Titel

Efficacy and Safety of Cryoballoon Ablation in Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction　― A Multicenter Study

Ist Teil von

• Circulation Journal, 2019/07/25, Vol.83(8), pp.1653-1659

Ort / Verlag

Japan: The Japanese Circulation Society

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Background:Second-generation cryoballoon (CB2)-based pulmonary vein isolation (PVI) has demonstrated encouraging results in the treatment of atrial fibrillation (AF). This study sought to assess data on the safety, efficacy and clinical success of CB2-based PVI in patients with heart failure (HF) and reduced ejection fraction (HFrEF).Methods and Results:CB2-based PVI was performed in 551 consecutive patients in 3 highly experienced EP centers. Patients with HF and LVEF ≤40% were included (HFrEF group, n=50/551, 9.1%). Data were compared with propensity score-matched patients without HF and preserved left ventricular EF (LVEF) (n=50, control group). The median LVEF was HFrEF: 37% (35, 40) and control: 55% (55, 55), P<0.0001. Major periprocedural complications were registered in 4/50 (8%, HFrEF group) and 3/50 (6%, control group), P=0.695. The 12-month freedom from AF recurrence was 73.1% (95% confidence interval (CI): 61–88, HFrEF group) and 72.6% (95% CI: 61–87, control group), P=0.25. NYHA class decreased from 2.4±0.8 (baseline) to 1.7±0.8 at 12-month follow-up (P<0.0001). LVEF improved from a median of 37% (35, 40) prior to ablation to a median of 55% (40, 55), P<0.0001.Conclusions:CB2-based PVI in patients with HFrEF appeared to be safe, was associated with comparable periprocedural complications and showed promising clinical success rates equal to those for patients with preserved LVEF. NYHA class and LVEF significantly improved at 12-month follow-up.